We have been busy as always at Rapid Novor sequencing antibody proteins for our clients around the globe. To help us keep up the pace and enhance our capability on experiment optimization and method development, we expand our team by welcoming Dr. David (Bin) Deng.
David obtained his Ph.D. degree in Analytical Chemistry of Pharmaceutical Science from Wuhan University, in China with the thesis “Single Cells Analysis Using Capillary Electrophoresis and Microfluidic Chip”. After graduation, he came to Canada to begin his postdoctoral research at the University of Alberta focusing on clinical molecular diagnosis with DNA and aptamers. Two years later, he continued his research at York University, Toronto, studying mass spectrometry (MS) for protein structure and dynamics, especially in epitope mapping by hydrogen-deuterium exchange (HDX-MS) and ion mobility (IM-MS).
David firmly believes in research for practical applications and novel pharmaceuticals to improve life quality of human beings. Striving in the rising Biopharmaceutical Industry, David decided to join us, the fast-growing biotechnology company, to work on de novo protein sequencing directly against research and therapeutic antibodies, candidates, and leads. As a Scientist at Rapid Novor, he is at the forefront of technology research and innovation. At the same time, he works with other team members to offer the highest quality services to our customers.
In his spare time, David loves hiking in great mountains, photography, reading and playing badminton. He believes love, good appetite, and healthy lifestyle make up the best recipe of a good life.